CARLOS
TAXONERA SAMSO
Profesor asociado de Ciencias de la Salud
Consorci Sanitari de Terrassa
Terrassa, EspañaPublicaciones en colaboración con investigadores/as de Consorci Sanitari de Terrassa (7)
2022
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
-
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2020
-
Switching to a second thiopurine in adult and elderly patients with inflammatory bowel disease: A nationwide study from the eneida registry
Journal of Crohn's and Colitis, Vol. 14, Núm. 9, pp. 1290-1298
2013
-
Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease
Gastroenterology, Vol. 145, Núm. 4